文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

尼伐地平治疗轻中度阿尔茨海默病:一项随机对照试验

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
PubMed 文献 · PLoS Med · 2018-09-24

NILVAD 是一项为期 18 个月、随机、安慰剂对照、双盲的 III 期试验,在 9 个欧洲国家 23 个学术中心纳入 511 例轻中度阿尔茨海默病患者,随机接受尼伐地平 8 mg 缓释胶囊或安慰剂每日一次。预设主要分析未显示尼伐地平对共同主要结局(ADAS-Cog 12 与 CDR-sb)有治疗获益(p = 0.465),探索性次要结局亦未见实质效应,药物总体安全可耐受。

要点

  • 尼伐地平 8 mg 每日一次未减缓轻中度阿尔茨海默病患者的认知下降。
  • 预设主要分析未显示共同主要结局获益(p = 0.465)。
  • 尼伐地平组不良事件与严重不良事件计数高于安慰剂组,但死亡率相似。

核心结论

  • 结果不支持尼伐地平用于轻中度阿尔茨海默病治疗。

研究设计与样本

  • NILVAD 为 18 个月、随机、安慰剂对照、双盲 III 期试验,在 9 个欧洲国家 23 个学术中心开展。
  • 筛查 577 例,511 例符合条件并随机分组(安慰剂 258 例,尼伐地平 253 例)。
  • 参与者年龄 >50 岁,符合 NINCDS-ADRDA 很可能阿尔茨海默病诊断,SMMSE 评分 ≥12 且 <27。
  • 随机接受 8 mg 缓释尼伐地平或匹配安慰剂,每日早餐后服用一粒试验胶囊,共 78 周。
  • 预设主要分析基于改良意向治疗人群(n = 498),主要结局为 ADAS-Cog 12 进展,CDR-sb 为门控共同主要结局。

主要发现

  • 预设主要分析未显示尼伐地平对共同主要结局有治疗获益(p = 0.465)。
  • 安慰剂组 ADAS-Cog 12 自基线下降:13 周 0.79(95% CI,-0.07-1.64),52 周 6.41(5.33-7.49),78 周 9.63(8.33-10.93)。
  • 尼伐地平组 ADAS-Cog 12 自基线下降:13 周 0.88(0.02-1.74),52 周 5.75(4.66-6.85),78 周 9.41(8.09-10.73)。
  • 探索性分析显示计划次要结局无实质效应,包括 CDR-sb 与 Disability Assessment for Dementia。
  • 尼伐地平组不良事件计数 1,129 versus 安慰剂组 1,030,严重不良事件 146 versus 101;死亡尼伐地平组 3 例、安慰剂组 4 例;因不良事件退出 14 例。

临床怎么用

  • 当前证据不支持将尼伐地平用于轻中度阿尔茨海默病的疾病修饰治疗。

局限性

  • 受试者已确立痴呆,且缺乏脑淀粉样蛋白生物标志物确认,可能纳入非阿尔茨海默病受试者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease. METHODS AND FINDINGS: NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of ≥12 and <27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-Cog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 weeks, 6.41 (5.33-7.49) at 52 weeks, and 9.63 (8.33-10.93) at 78 weeks and on nilvadipine was 0.88 (0.02-1.74) at 13 weeks, 5.75 (4.66-6.85) at 52 weeks, and 9.41 (8.09-10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid. CONCLUSIONS: The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease. TRIAL REGISTRATION: Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Lawlor B, Segurado R, Kennelly S, et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med. 2018. PMID: 30248105. doi:10.1371/journal.pmed.1002660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。